Jubilant Pharmova Share Price

Jubilant Pharmo

CMP as on 20-May-22 15:29

₹ 412.00
12.30 3.08%

Open

₹ 402.05

Turnover (lac)

₹ 244

Prev. Close

₹ 399.70

Day's Vol (shares)

₹ 59,216

Day's Range (₹)

₹ 400.00
₹ 417.00

CMP as on20-May-22 15:29

₹ 412.00
12.15 3.04%

Open

₹ 405.00

Turnover (lac)

₹ 50

Prev. Close

₹ 399.85

Day's Vol (shares)

₹ 7,171

Day's Range

₹ 401.85
₹ 415.00

Corporate Action

Go
Purpose AGM Date Announcement Date Book Closure Start Date Book Closure End Date
Board Meeting - 27-Jan-2022 - -
Jubilant Pharmova Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/02/2022 inter alia to consider and approve In terms of Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 (the Listing Regulations) we wish to inform you that a meeting of the Board of Directors of the Company is scheduled to be held on Friday February 4 2022 to inter-alia consider Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended December 31 2021. This is for your information and record. In terms of Regulation 33 read with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the Listing Regulations), we wish to inform you that the Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter ended December 31, 2021 were approved by the Board of Directors of the Company at its meeting held today at 12.15 p.m. and concluded at 3.20 p.m. Pursuant to the applicable provisions of the Listing Regulations, we enclose the following: 1. The Unaudited Financial Results (Standalone and Consolidated) for the quarter ended December 31, 2021; 2. Limited Review Reports on the Unaudited Financial Results (Standalone and Consolidated) for the said quarter; and 3. Copies of the Press Release and Presentation. We request you to take the same on records. (As Per BSE Announcement Dated on 04/02/2022)
Board Meeting - 14-Oct-2021 - -
Quarterly Results Jubilant Pharmova Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 22/10/2021 ,inter alia, to consider and approve In terms of Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the Listing Regulations), we wish to inform you that a meeting of the Board of Directors of the Company is scheduled to be held on Friday, October 22, 2021, to inter-alia consider Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half-year ended September 30, 2021. Dear Sirs, In terms of Regulation 33 read with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the Listing Regulations), we wish to inform you that the Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter and half year ended September 30, 2021 have been approved by the Board of Directors of the Company at its meeting held today at 1:15 p.m. and concluded at 2.45 p.m. Pursuant to the applicable provisions of the Listing Regulations, we enclose the following: 1. The Unaudited Financial Results (Standalone and Consolidated) for the quarter and half year ended September 30, 2021; 2. Limited Review Reports on the Unaudited Financial Results (Standalone and Consolidated) for the said period; and 3. Copies of the Press Release and Presentation. (As Per BSE Announcement dated on 22.10.2021)
Board Meeting - 15-Jul-2021 - -
Jubilant Pharmova Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/07/2021 ,inter alia, to consider and approve In terms of Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the Listing Regulations), we wish to inform you that a meeting of the Board of Directors of the Company is scheduled to be held on Friday, July 23, 2021, to inter-alia consider Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30, 2021. In terms of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of Jubilant Pharmova Limited (JPM), at its meeting held on July 23, 2021, has approved the demerger of the Active Pharmaceutical Ingredients (API) undertaking of Jubilant Generics Limited (JGL - a wholly owned subsidiary of the Company) and vesting of the same with JPM, on a going concern basis (Proposed Demerger), to be implemented through a scheme of arrangement between JGL and JPM and their respective shareholders and creditors under Sections 230 to 232 and other applicable provisions of the Companies Act, 2013 (Proposed Scheme). The details as required to be disclosed under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular dated September 9, 2015, are enclosed at Annexure A. Kindly take the above information on record. (As Per BSE Announcement Dated on 23.07.2021)
Board Meeting - 28-May-2021 - -
Jubilant Pharmova Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/06/2021 ,inter alia, to consider and approve In terms of Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the Listing Regulations), we wish to inform you that a meeting of the Board of Directors of the Company is scheduled to be held on Friday, June 4, 2021, to inter-alia consider: 1. Audited Standalone and Consolidated Financial Results of the Company for the quarter and year ended March 31, 2021; and 2. Recommendation of Dividend for the Financial Year ended March 31, 2021. Pursuant to the provisions of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company has, at its meeting held today i.e. on June 4, 2021, recommended a dividend of Rs. 5 (Rupees five only) per equity share of Re.1 each for the year ended March 31, 2021. The dividend, if approved by the shareholders at the ensuing Annual General Meeting of the Company, will be paid / despatched on or before October 20, 2021. We request you to take the same on record. Pursuant to the provisions of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company has, at its meeting held today i.e. on June 4, 2021, recommended a dividend of Rs. 5 (Rupees five only) per equity share of Re.1 each for the year ended March 31, 2021. The dividend, if approved by the shareholders at the ensuing Annual General Meeting of the Company, will be paid / despatched on or before October 20, 2021. We request you to take the same on record. (As Per BSE Announcement Dated on 04.06.2021)
Open ZERO Brokerage Demat Account Open Demat Account

  • 0

    Per Order for ETF & Mutual Funds Brokerage

  • 20

    Per Order for Delivery, Intraday, F&O, Currency & Commodity